Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital opioid treatment study tests best way to help patients

NCT ID NCT04921787

Disease control Sponsor: Gavin Bart Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at two different approaches to help community hospitals start treating opioid use disorder in patients. One approach is basic training and education, while the other adds extra support like practice facilitation. The goal is to see which method works better at getting patients to continue treatment after they leave the hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Training and education vs. practice facilitation
What this could lead to
If successful, this could show how to effectively implement opioid treatment programs in community hospitals, increasing access to care.
What could go wrong
This is a small, early-stage implementation study with only 24 hospitals, so results may not apply broadly. It tests strategies, not a direct treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be a community hospital deemed by the lead investigators to be in the region of a site/hub. Region will usually be defined as state unless a compelling case can be made as to geographic feasibility of implementing the intervention and access to relevant Medicaid data. 2. Be willing to identify a site champion to promote and adopt change that can address OUD in hospitalized patients. 3. Have hospital personnel who state that their institution is interested in and would be willing to work to implement MOUD prior to hospital discharge. 4. Commit to having buprenorphine-waivered prescribers willing and able to write prescriptions to bridge discharged patients to post-discharge OUD treatment, or available direct entry into outpatient MOUD with methadone or buprenorphine. 5. Have hospital staff who express willingness to engage with a site/hub team for training and for data collection. 6. Be willing to be randomized to low-intensity or high-intensity implementation support. 7. Provide inpatient general medical care. 8. Have sufficient numbers of Medicaid OUD discharges (any listed diagnosis; sufficient is defined as at least enough such that when added to the other hospitals in the region there are on average 100 discharges per year). Medicaid data must capture at least 3 discharge diagnoses, outpatient MOUD, and be available within no more than 12 months of discharge. Exclusion Criteria: 1. Have an ACS routinely prescribing MOUD at discharge. 2. Have an existing, functioning HBOT program or be imminently starting an HBOT initiative, as confirmed by the investigator team. 3. Be a Veterans Affairs hospital.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder, moderate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma opiate dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use disorder, moderate Opioid use disorder, severe Substance use disorders

Contacts and locations

Locations

  • Boston University

    Boston, Massachusetts, 02119, United States

  • Hennepin Healthcare Research Institute

    Minneapolis, Minnesota, 55404, United States

  • New York University

    New York, New York, 10016, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.